This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Quartuccio, L Articles by De Vita, S Search for Related Content PubMed PubMed Citation Articles by Quartuccio, L Articles by De Vita, S Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOSPORIN A Medline Plus Health Information Lupus Platelet Disorders Social Bookmarking                         What's this?

Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus

Rheumatology Clinic, DPMSC, University of Udine, Italy

S Sacco

Rheumatology Clinic, DPMSC, University of Udine, Italy

N Franzolini

Rheumatology Clinic, DPMSC, University of Udine, Italy

A Perin

Rheumatology Clinic, DPMSC, University of Udine, Italy

G Ferraccioli

Division of Rheumatology, Catholic University of Sacred Heart, School of Medicine, Rome, Italy

S De Vita

Rheumatology Clinic, DPMSC, University of Udine, Italy, salvatore.devita{at}med.uniud.it

Thrombocytopenia frequently complicates systemic lupus erythematosus (SLE), and its long-term management may be problematic. Intravenous immunoglobulins and high doses of steroids are often effective as induction therapy, but thrombocytopenia frequently relapses during steroid tapering. Several immunosuppressive agents have been evaluated as induction or maintenance therapy in small series or in case reports. We describe six consecutive unselected SLE patients where cyclosporin-A (CyA) was effective and safe in the long-term management of thrombocytopenia and allowed steroid tapering. One relapse occurred during CyA reduction and responded to CyA dose adjustment. Steroids could be stopped in three out of six patients, and were maintained at very low doses in the remaining patients. CyA was stopped in one patient after one year of treatment, without relapse at month 11+ from discontinuation. No severe side effects were documented. Overall, these data suggest that CyA may prove to be an effective and safe therapeutic option for SLE-related thrombocytopenia.

Key Words: cyclosporin-A • systemic lupus erythematosus • thrombocytopenia

Lupus, Vol. 15, No. 2, 76-79 (2006)
DOI: 10.1191/0961203306lu2266oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Z Wang, Z Tang, H. Zhang, W. Hu, Z. Liu, and L. Li Clinicopathological characteristics of familial SLE patients with lupus nephritis Lupus, March 1, 2009; 18(3): 243 - 248. [Abstract] [PDF]